Pharming Group is a Dutch rare disease company whose midyear print recasts the equity from a growth compounder into a transition story. Management reduced full year revenue guidance after an oral on-demand hereditary angioedema therapy spent a year in the American market. That cut arrived after the prior range was reaffirmed in May, and it tells investors that RUCONEST is no longer a dependable growth engine even if the installed patient base is holding. The investment debate is whether Joenja and two late year immunology readouts can replace that engine before the franchise erodes further.
The franchise still produces the large majority of sales. Second quarter revenue slipped three percent to $90 million as RUCONEST declined and Joenja grew at a forty percent clip. Sequential recovery in the older product and a rebound in new enrollments are the evidence management cites for second half stabilization. A manufacturing inventory write-down and a $30 million guidance reduction both say underlying demand is softer than the retained patient count implies.
Adjusted operating profit stayed positive even after nearly $9 million of incremental investment versus the year ago quarter. Cash still covers the current pipeline and the prelaunch spend. The next tests are the October pediatric decision for Joenja, two Phase II immunodeficiency readouts later this year, and whether third quarter RUCONEST actually stops declining. The open question is whether the market gets a cash engine plus a larger immunology option, or a shrinking single franchise with expensive science attached.